138 related articles for article (PubMed ID: 34742015)
1. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
3. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors.
Chen Y; Lei H; Li T; Cui Y; Wang X; Cao Z; Wu H; Zhai X
Bioorg Med Chem; 2021 Sep; 46():116362. PubMed ID: 34428714
[TBL] [Abstract][Full Text] [Related]
6. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
7. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model.
Lei H; Li Z; Li T; Wu H; Yang J; Yang X; Yang Y; Jiang N; Zhai X
Bioorg Chem; 2022 Mar; 120():105590. PubMed ID: 34998121
[TBL] [Abstract][Full Text] [Related]
8. Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors.
Jia F; Lei H; Chen Y; Li T; Xing L; Cao Z; Zhai X
Bioorg Med Chem; 2020 Nov; 28(22):115795. PubMed ID: 33032188
[TBL] [Abstract][Full Text] [Related]
9. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
10. Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.
Cao P; Aoki Y; Badri L; Walker NM; Manning CM; Lagstein A; Fearon ER; Lama VN
J Clin Invest; 2017 Apr; 127(4):1517-1530. PubMed ID: 28240604
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Lei H; Wang X; Zhao G; Li T; Cui Y; Wu H; Yang J; Jiang N; Zhai X
Eur J Med Chem; 2022 Jun; 236():114307. PubMed ID: 35436669
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
[TBL] [Abstract][Full Text] [Related]
15. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X
Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537
[TBL] [Abstract][Full Text] [Related]
16. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
17. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
20. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X
Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
